These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8105945)

  • 1. Lipid-lowering effects of lovastatin in CAPD patients.
    Jacobs RH; Lal SM; Nolph KD
    Adv Perit Dial; 1993; 9():288-90. PubMed ID: 8105945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperlipidemia in continuous ambulatory peritoneal dialysis patients.
    Lal SM
    ASAIO J; 1993; 39(2):87-8. PubMed ID: 8324266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of lipid profiles in long-term peritoneal dialysis.
    Olivares J; Cruz C; Gas JM; Prados MC; Perdiguero M; Caparros G; Santiago C; Franco A
    Adv Perit Dial; 1992; 8():373-5. PubMed ID: 1361826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia].
    Zambrana García JL; López Miranda J; Anguita Sánchez M; Blanco Cerrada J; Vallés Belsúe F; Casares Mediavilla J; Muñoz Carvajal I; Jiménez Perepérez JA; Pérez Jiménez F
    Rev Esp Cardiol; 1996 Dec; 49(12):892-8. PubMed ID: 9026840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of apolipoprotein E genotype on lipid and lipoprotein levels in continuous ambulatory peritoneal dialysis patients.
    Choi KH; Song HY; Shin SK; Noh H; Kang SW; Kim JH; Lee HY; Han DS
    Adv Perit Dial; 1999; 15():243-6. PubMed ID: 10682111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of lipid levels with mortality in patients on chronic peritoneal dialysis.
    Habib AN; Baird BC; Leypoldt JK; Cheung AK; Goldfarb-Rumyantzev AS
    Nephrol Dial Transplant; 2006 Oct; 21(10):2881-92. PubMed ID: 16735386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
    Prata MM; Nogueira AC; Pinto JR; Correia AM; Vicente O; Rodrigues MC; Miguel MJ
    Clin Nephrol; 1994 May; 41(5):277-83. PubMed ID: 8050207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin in the treatment of hypercholesterolemia in CAPD.
    Krane NK; Stock G; Caballero M; Starks E
    Adv Perit Dial; 1992; 8():362-4. PubMed ID: 1361823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
    O'Connor PJ; Rush WA; Trence DL
    J Fam Pract; 1997 May; 44(5):462-7. PubMed ID: 9152263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality.
    Taskapan MC; Taskapan H; Sahin I; Keskin L; Atmaca H; Ozyalin F
    Ren Fail; 2007; 29(2):147-54. PubMed ID: 17365928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
    Fiorini F; Patrone E; Castelluccio A
    Clin Ter; 1994 Sep; 145(9):213-7. PubMed ID: 7813167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients?
    Nauck M; Krämer-Guth A; Bartens W; März W; Wieland H; Wanner C
    Clin Nephrol; 1996 Nov; 46(5):319-25. PubMed ID: 8953121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hyperlipidemia in a cohort of CAPD patients. Italian Cooperative Peritoneal Dialysis Study Group (ICPDSG).
    Cocchi R; Viglino G; Cancarini G; Catizone L; Favazza A; Tommasi A; Salomone M; Segoloni GP; Torpia R; Giangrande A
    Miner Electrolyte Metab; 1996; 22(1-3):22-5. PubMed ID: 8676819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of lipid lowering diet on serum lipids in peritoneal dialysis patients].
    Jedrzejowski A; Lis D; Majcher A; Ziółkowska H; Roszkowska-Blaim M; Wajda M; Sieniawska M
    Pol Merkur Lekarski; 2000 Apr; 8(46):266-7. PubMed ID: 10897643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.